Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial

Background To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic pr...

Full description

Saved in:

Bibliographic Details
Published in:	World journal of urology Vol. 32; no. 5; pp. 1287 - 1294
Main Authors:	Verhagen, Paul C. M. S., Wildhagen, Mark F., Verkerk, Annet M., Vjaters, Egils, Pagi, Hembo, Kukk, Leonhard, Bratus, Dejan, Fiala, Richard, Bangma, Chris H., Schröder, Fritz H., Mickisch, Gerald H. J.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-10-2014 Springer Nature B.V
Subjects:	Aged Androgen Antagonists - administration & dosage Bone Neoplasms - drug therapy Bone Neoplasms - secondary Cyproterone Acetate - administration & dosage Humans Male Medicine Medicine & Public Health Nephrology Oncology Original Article Prostatic Neoplasms - pathology Urology Cyproterone acetate (CPA) Metastatic prostate cancer Androgen deprivation therapy (ADT) Intermittent ADT
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!